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Autoimmunehepatitis(AIH)isachronicinﬂammatorydisordercharacterized byperiportalinﬂammation,elevatedimmunoglob-
ulins, autoantibodies, and a dramatic response to immunosuppression. An environmental agent is hypothesized to trigger an
immune-mediated attack directed against liver antigens in genetically predisposed individuals. A plethora of clinical presentations
can be seen ranging from chronic indolent disease to fulminant hepatic failure, and diagnosis requires exclusion of other causes
of liver disease. Corticosteroid therapy must be instituted early and modiﬁed in an individualized fashion. Treatment decisions
are often complicated by the diverse clinical manifestations,uncertainty about natural history, evolving ideas about treatment end
points,and a multitudeofalternative immunosuppressiveagents.Achievingnormalliver tests andtissueis the idealtreatment end
point,but needs tobe weighed againstthe riskofside eﬀects. Decompensated patientsmaybeneﬁt fromearlylivertransplantation.
Long-termprognosisisexcellent withearlyandaggressiveinitiationoftherapy. OurpaperdiscussesAIH,givingadetailedoverview
ofitsclinicalpresentation,riskfactors,immunopathogenesis,up-to-date diagnosticcriteria,currentupdates intherapywithabrief
discussionof AIH in pregnancy, and long-term implications for cirrhosis and hepatocellular carcinoma in AIH patients.
1.Background
Autoimmune hepatitis (AIH) is a chronic inﬂammatory
disease of unknown etiology characterized by the presence
of circulating autoantibodies, hypergammaglobulinemia,
necroinﬂammatory changes on hepatic histology, and a
dramatic response to immunosuppressive therapy. Earliest
descriptions include those by Amberg in 1942 [1]a n d
Leber in 1950 [2] describing a form of chronic liver disease
prevalent among young women and characterized by an
excessive increase in serum protein and gamma-globulins.
In 1951, Kunkel et al. termed the condition “hypergam-
maglobulinemic chronic hepatitis” [3]. Since then, it has
been known by various names including chronic active
hepatitis, chronic aggressive hepatitis, plasma cell hepatitis,
and autoimmune chronic active hepatitis. Cowling and
Mackay coined the term “lupoid hepatitis” after they noted
the association of this entity with autoimmune syndromes
and the LE cell phenomenon [4].
The disease is rare with a mean incidence of 1-2 per
100,000 and a point prevalence of 11–17 per 100,000 [5, 6].
Although more frequently seen in young women (sex ratio
3.6:1), it can aﬀect children and adults of all ages and eth-
nicities [7, 8]. A minority of patients may present with acute
liverfailureandneedlivertransplantation, butforthemajor-
ity, the prognosis of AIH is good and mostly determined
by response to corticosteroid therapy. In general, long-
term survival and average life expectancy are excellent and
estimated to be comparable to the normal population [9].
2.Classiﬁcation
The classiﬁcation of AIH into diﬀerent types is based on
serum autoantibody proﬁles. Type I AIH is characterized by
the presence of antinuclear antibody (ANA), anti-smooth
muscle antibody (SMA), or both and constitutes 80% of
AIH cases. About 25% have cirrhosis at presentation, and
association with other autoimmune diseases is common2 Hepatitis Research and Treatment
Table 1: HLA associationsin autoimmunehepatitis.
HLA Association
(Reference) Ethnicity/Comments AIH Type
Number of
patients
studied
Patients Controls
HLA-DRB1∗0401 [15]
(i) European and North American
Increases susceptibility to AIH Type I
in Caucasians
(ii) HLA-DR3 associated with younger
age at presentation, diminished
response to therapy and more frequent
liver failure requiring liver
transplantationas compared to
HLA-DR4
I 119 45% 23%
HLA-DRB3∗0101 [15] European and North American I 119 58% 25%
HLA-DRB1∗0404 [16] Mexican I 30 36.7% 7.4%
HLA-DRB1∗0405 [17] Japanese — 49 67.3% 29.6%
HLA-DRB1∗07 [18] Brazil II 28 68% 20%
HLA-B14 [19] Germany II 19 26% 4%
(celiac disease, ulcerative colitis, autoimmune thyroid dis-
ease) [10, 11]. Type 2 AIH is characterized by the presence
of anti-liver kidney microsomal (LKM) 1 and/or anti-LKM3
and/or anti-liver cytosol 1 (LC1) [12, 13] antibodies. Most
patients are children, acute severe presentation can occur,
and progression to cirrhosis commonly ensues [14].
In patients who are negative for conventional antibodies
and AIH is strongly suspected, additional tests can be done
including perinuclear antineutrophil cytoplasmic antibodies
(pANCA), actin (anti-actin), soluble liver antigen (anti-
SLA), asialoglycoprotein receptor (anti-ASGPR), chromatin,
and liver cytosol type 1 (anti-LC1). In our experience,
10–15% patients do not have either ANA, SMA, or anti-
LKM1 at presentation, but 25% of these will have detectable
conventional antibodies later in their course. Another 10–
20% of the seronegative patients at presentation will have
pANCAoranti-SLA.Overall, approximately5% will haveno
currently available markers long term.
2.1.Etiopathogenesis . Althoughtheexactetiopathogenesisis
unknown, AIH, like many autoimmune diseases, is thought
to be caused by environmental triggers and failure of
immune tolerance mechanisms in a genetically susceptible
host.These triggersmaybeofviralordrugetiology,butmost
cases have an unknown trigger. Triggers may share epitopes
that resemble self-antigens, and molecular mimicry between
foreign antigens and self-antigens is the most frequently
proposed initiating mechanism in type 2 AIH where the
autoantigen is known. Repeated exposures to the triggering
antigen, in turn, may trigger autoreactive organ-speciﬁc
responses.
2.2. Genetic Associations. AIH is a complex polygenic disease
and diﬀerent populations may have diﬀerent genetic and
environmental triggers and genetic association varies in
study populations. The human leukocyte antigen (HLA)
genes on chromosome 6 are the most commonly described
associationwithAIH.HLAassociations varybyethnicityand
have been summarized in Table 1. HLA may be associated
with age at presentation, disease severity, and response to
therapy. How the HLA genes predispose to disease is not
exactly known but is likely due to their role in autoreactive T
cell selection and autoantigenic peptide presentation. Diﬀer-
ent susceptibility alleles like HLA DRβ1∗0301, DRβ1∗0401,
DRβ1∗0404, and DRβ1∗0405 share a “common motif,”
namely, amino acids LLEQKR or LLEQRR at position 67-
72 of class II HLA, whereas the resistant alleles DRβ1∗1501
encodes ILEQAR [20, 21]. In contrast, HLA-DRβ1∗1501,
encodes for the ILEQAR motif [21] and is associated with
protection from AIH. Substitution of a lysine or arginine to
alanine at position 71 is postulated to change the polarity
and charge of the peptide binding groove of the major his-
tocompatibility complex thereby inﬂuencing autoantigenic
peptide presentation. However, these associations are not
absolute and signiﬁcant geographic diﬀerences exist, for
example, in Japan DR2(DRB1∗1501) is a weak susceptibility
rather than a resistance allele [22]a n di nS o u t hA m e r i c a n
children DRB1∗1301 is a strong susceptibility allele [23].
Furthermore, patient numbers in many HLA studies are low.
A form of AIH can be seen in 20% of patients with
autoimmune polyendocrinopathy-candidiasis-ectodermal
dystrophy (APECED) syndrome. APECED is a monogenic,
autosomal recessive disorder characterized by hypoparathy-
roidism, adrenal insuﬃciency, and chronic mucocutaneous
candidiasis. APECED is caused by mutations in a tran-
scription factor relevant to immune tolerance called AIRE
(autoimmune regulator) on chromosome 21q223. AIRE is
expressed in medullary epithelial and dendritic cells within
the thymus and regulates clonal deletion of autoreactive
T cells. The liver autoantigens associated with APECED
are cytochrome P450 (CYP) 1A2, CYP2A6, and CYP2D6
[24–26]. This is the only syndrome involving AIH that
exhibits a Mendelian pattern of inheritance, and genetic
testing and counseling for the patient and family members
are warranted [24].Hepatitis Research and Treatment 3
2.3. Immunopathogenesis. Full insight into the pathogenesis
of AIH remains elusive. The liver is part of the lymphoid sys-
tem with the normal lymphocyte populationmainly residing
in the portal tracts. AIH is an inﬂammatory disorder of the
liver involving multiple components of the immune system
including T cells, B cells, and cytokines. Hepatocytesisolated
from AIH patients are coated with immunoglobulins and
are susceptible to antibody-dependent cellular cytotoxicity
(ADCC) when exposed to autologous mononuclear cells
bearing Fc receptors [40]. CYP2D6, an important cytoplas-
mic enzyme is targeted by anti-LKM1 antibodies and plays a
crucial role in liver damage. Mice immunized with plasmid
containing human CYP2D6 antigenic region and human
formiminotransferase cyclodeaminase (another autoanti-
gen), have established a murine model for autoimmune
hepatitis type 2 [41]. These mice develop autoantibodies,
elevation in transaminases, along with portal and periportal
inﬂammatory inﬁltrate. Another model using adenovirus
vector containing human CYP2D6 infection of CYP2D6
transgenic mice had focal hepatocyte necrosis and hepatic
ﬁbrosis [42]. These models will aid the developmentof more
therapeutic options in the management of autoimmune
hepatitis.
Studies have demonstrated presence of cytotoxic cells
in both T and non-T cell compartment of peripheral blood
from AIH patients. This cytotoxic activity is higher in
patients with active disease but seen in only 40% of patients
in remission [43]. Patients with AIH have a ten fold higher
frequency of liver-speciﬁc T cells compared to normal
subjects [32]. In patients with predisposing HLA allele
DRβ1∗0701, CD4 T cells are able to recognize autoantigen
CYP2D6 and secrete interferon-γ [44]. In addition CD8+ T
cells have been isolated from portal tract inﬁltrate. CD8 T
cellshave cytotoxiccapability,are capable ofsecreting IFN-γ,
and their responses correlate with disease activity [45].
Defects in numbers and function of regulatory cells (T
regs) have been demonstrated in AIH [46]. T regulatory cells
normally control or limit immune responses by acting as
immunoregulators, preventing the proliferation and eﬀector
function of autoreactive T cells. In patients with AIH, T-
regs are defective both in number and function. The number
of T regs is decreased more so at disease presentation than
at drug-induced remission. Their level correlates inversely
with levels of anti-SLA and anti-LKM-1 autoantibody titers
[46]. The T reg numbers and function improve during
remission but are never normal. Longhi et al. in their study
demonstrated that Tregs generated under CYP2D6-speciﬁc
conditions and cocultured with semimature dendritic cells
are highly eﬀective at controlling autoreactive T cells, thus
providing a potential tool for immunotherapy in type 2
AIH [47]. T regs may, therefore, be an attractive therapeutic
target, but more studies are needed to elucidate this better.
2.4. Environmental Factors. Several drugs have also been
implicated as triggers for AIH including Inﬂiximab [48],
Minocycline [49], Atorvastatin [50], diclofenac,isoniazid, α-
methyldopa, nitrofurantoin, and propylthiouracil and Hep-
atitis A vaccine [51]. Herbal agents such as black cohosh and
dai-saiko-to have been proposed to induced AIH [52]. The
exact reason for drug-induced AIH is not known but may
be due to hepatotoxic eﬀect of these chemicals, upregulation
of proteins expression (P450s, immunoregulatory proteins),
or related to the drug acting as a hapten by modifying the
hepatic protein, making them immunogenic. Drug-induced
AIH may improve after discontinuation of oﬀending agent,
thus initial observation is warranted.
Viruses such as hepatitis A, B, or C, in addition to
measles have been implicated as triggers for AIH. ANA
and SMA can occur in diverse causes of acute and chronic
hepatitis including alcoholic, nonalcoholic fatty liverdisease,
and viral hepatitis. They are usually low titer, background
reactivities that should not alter diagnosis or management.
If clinical concern for autoimmune hepatitis exists, antiactin
antibodies can be checked as they increase the speciﬁcity
of SMA testing for diagnosing AIH [53]. Anti-LKM1 has
been found in as many as 10% of patients with chronic
hepatitis C and is diﬀerent from the anti-LKM1 found in
classic autoimmune hepatitis [54]. Molecular mimicry at
the B-cell level between a structural motif of CYP2D6 and
HCV proteins could explain the production of anti-LKM1
antibodies in HCV-infected patients [55].
3.ClinicalManifestations
Women constitute at least 70% of cases, and 50% are
younger than 40 years; however, age at onset may range from
infancy to the elderly. AIH has diverse presentations with
25–34% of patients presenting with asymptomatic liver test
abnormalities. Forty percent of patients may present with an
acute onset, but the presentation of severe fulminant hepatic
f a i l u r ei sr a r e[ 56]. Children or elderly more commonly
present with cirrhosis. Presenting symptoms may include
fatigue, lethargy, malaise, arthralgia of small joints, anorexia,
nausea, abdominal pain, and dark urine. These symptoms
are nonspeciﬁc and contribute to the delay in diagnosis.
Asymptomatic patients commonly become symptomatic,
and thus need to be monitored. Clinical manifestations
m a yv a r yb ye t h n i c i t y ;t h ep r e s e n t a t i o ni sa c u t ea n di c t e r i c
in Alaskan [57] native patients, cholestatic in Aboriginal
North American, African, Asian, and Arab patients, mild in
Japanese patients [58], but severe and rapidly progressive in
Somali patients [59] .C i r r h o s i so c c u r si na sm a n ya s8 5 %o f
black North American patients [60]. Diﬀerences in etiologic
agents and genetic factors may account for this variation.
Physical examination may be normal, but may also
reveal hepatomegaly, splenomegaly, jaundice, and stigmata
of chronic liver disease. Findings such as acne, hirsutism,
obesity, and amenorrhea in young women are rarely seen.
Other autoimmune diseases such as Hashimoto thyroiditis,
type 1 diabetes, rheumatoid arthritis, systemic lupus erythe-
matosus, ulcerative colitis/Crohn’s disease, and celiac disease
can be seen in 20% of patients [61].
Chung et al. described a novel subtype of AIH character-
ized by inﬁltration of IgG4-positive plasma cells [62]. This
subtype is associated with higher serum levels of IgG, AIH
severity scores, and, more importantly, an excellent response
to prednisone therapy for induction and maintenance of
remission. Positive IgG4 staining is suggested by the authors4 Hepatitis Research and Treatment
as a surrogate marker for the subtype of AIH that may
respond well to corticosteroid therapy alone. Whether this
is a form of classic AIH or a distinct entity awaits a more
extensive description of its clinical and immunohistological
features.
4.Diagnosisof AutoimmuneHepatitis
The diagnosis of AIH requires the presence of characteristic
clinical features and exclusion of other chronic liver condi-
tions, such as viral hepatitis, drug-induced hepatitis, fatty
liver disease, alcohol related liver disease, Wilson’s disease,
alpha 1 antitrypsin deﬁciency, or hemochromatosis.
4.1. Laboratory Features. Laboratory studies typically show
elevation of aspartate aminotransferase (AST) and alanine
aminotransferase (ALT) levels, but levels are generally
<500U/L, but on rare occasions can range between 500–
1000U/L. Some patients may have high conjugated bilirubin
andalkalinephosphatasenecessitatingexclusionofextrahep-
atic biliary obstruction, cholestatic forms of viral hepatitis,
drug-induced disease, primary biliary cirrhosis (PBC), and
primary sclerosing cholangitis (PSC). The alkaline phos-
phatase rarely exceeds 4 X normal and generally remains <2
times normal. Another characteristic laboratory feature of
AIH is hypergammaglobulinemia, with a selective increase
in IgG, which is 1.2–3.0 times higher than the upper level
of normal [63]. It should be noted that HLA typing has not
been endorsed as a diagnostic or prognostic tool.
4.2. Autoantibodies. The characteristic circulating autoan-
tibodies seen in AIH include ANA, SMA, and (LKM-1)
autoantibodies. A list of the important autoantibodies and
their autoantigenic targets is summarized in Table 2 [27].
They are helpful in diagnosis as well as for classiﬁcation of
AIH into type 1 and type 2 diseases. The reader is referred to
excellent reviews for description of methodology, sensitivity,
and assay performance [27, 39, 64]. Except for pANCA,
which is readily available and can be positive in 50–90%
of type I AIH, only antiactin can be easily in measured in
some laboratories. Recently, antibodies to cyclic citrullinated
peptides (CCP) have been described in 9–11% of patients
with AIH in absence of rheumatoid arthritis. These patients
have a propensity to develop cirrhosis and liver failure
[65]. Antimitochondrial antibodies are sometimes present in
patientswith AIH and an overlap syndrome of AIHand PBC
should be considered in these patients [66].
4.3. Diagnostic Scoring System. Ad i a g n o s t i cs y s t e mw a s
proposed by the International AutoimmuneHepatitis Group
(IAIHG) in 1993 and subsequently updated in 1999 [66, 67].
In 2008, they proposed a simpliﬁed set of diagnostic criteria
to facilitate early recognition and initiation of adequate
immunosuppressivetreatment[68].Theseincludedthepres-
ence of speciﬁc autoantibodies (ANA, SMA, LKM antibody,
SLA antibody) in moderate to high titers, hypergammaglob-
ulinemia, typical histological pattern on liver biopsy, and
 
Figure 1: Interface hepatitis demonstrated by inﬁltration of
lymphoplasmacytic inﬁltrate into the hepatic parenchyma typical
of autoimmune hepatitis.
exclusion of viral hepatitis. These criteria have a lower sensi-
tivity (85% versus 100%) but higher speciﬁcity (99% versus
93%) than the original criteria and are good at identifying
patientswithall typicalcharacteristics ofaclassiccaseofAIH
[69, 70]. However, Miyake et al. showed that 30% of males,
23% of patients with acute clinical presentation, and 46%
patients negative for ANA were not diagnosed with AIH by
simpliﬁed criteria even though they met the original criteria
[69].Therefore, itfails toadequatelyidentifycaseswith atyp-
ical features which is an important point to keep in mind.
4.4. Histological Diagnosis. The histologic hallmark of AIH
is a lymphoplasmacytic periportal inﬁltrate invading the
limiting plate, also called piecemeal necrosis or “interface
hepatitis” (Figure 1) that eventually progresses to lobular
hepatitis. There is often an abundance of plasma cells and
eosinophilsare frequentlypresent.The portal lesiontypically
spares the biliary tree. A lobular, or panacinar hepatitis is
also frequently observed. Fibrosis is present in all but the
mildest forms of AIH. It causes distortion of the hepatic
lobule and the appearance of regenerative nodules, resulting
in cirrhosis [71]. Many patients with acute presentation may
have chronic features on liver biopsy indicating a subclinical
phase of disease and several patients with mild clinical
disease may have advanced ﬁbrosis on biopsy. Of important
note is the fact that the ﬁbrosis and even cirrhosis in AIH
is reversible to a signiﬁcant degree with immunosuppressive
therapy unlike in other chronic liver diseases.
4.5. Radiology. There are no speciﬁc imaging techniques
to conﬁrm the diagnosis of autoimmune hepatitis. In
adults with both AIH and IBD, cholangiographic changes
suggestive of PSC are present in up to 44% patients and
may aﬀect therapy and prognosis [72]. In children with AIH,
autoimmune sclerosing cholangitis can be present with or
without inﬂammatory bowel disease [73].
5.Therapy
5.1.Indications forTreatment. AIHisatreatablechronicliver
disease in the majority of the cases. Untreated patients withHepatitis Research and Treatment 5
Table 2: Autoantibodies in autoimmune hepatitis.
Autoantibody Molecular target Prognostic value Reference
Antiliver kidney microsomal
(LKM1) Cytochrome 450 2D6 Diagnostic for AIH type 2 [27]
Anti-LKM3 Uridine diphosphate
glucuronosyltransferase
7% of patients with AIH associated with
viral hepatitis C [28]
Antismooth muscle antibody
Actin and non-actin
components (vimentin,
Skeltin)
Diagnostic marker for type 1 AIH
Antiactin Polymerized F-actin
(1) Subset of smoothmuscle antibodies
(2) Children: treatment dependence and
progression to liver failure
(3) Adults: early onset and severe disease
(4) Severe clinical and histologicaldisease if
reactive to actin and α-actinin, anti-ss DNA
antibodies can be seen as well.
[29–31]
Anti-soluble liver antigen
(SLA)
Sep (O-phosphoserine)
tRNA: SEC(selenocysteine)
tRNA synthase
(1) High speciﬁcity, may be present when
other markers are absent
(2) Predictor of relapse and treatment
dependence
(3) Associated with DRB1∗0301
(4) Higher frequency of death from liver
failure.
[32, 33]
Antiliver cytosol type 1 (LC1) Formiminotransferase
cyclodeaminase
(1) Present when other markers like ANA,
SMA, LKM1 absent
(2) Early age of onset and concurrent
immune disease
(3) Marked liver inﬂammationand rapid
progression to cirrhosis
[34, 35]
Anti-asialoglycoprotein
receptor (ASGPR) Asialoglycoprotein receptor (1) Correlate with histologicalactivity [36]
Antibody to histone and
double stranded DNA
(dsDNA)
Histone, dsDNA (1) Patients with anti-dsDNA fail
corticosteroid treatment more frequently [37]
Anti-chromatin Chromatin
(1) Occur in association with ANA
(2) May deﬁne a subset of ANA positive
patients that are treatment dependent
(3) Predictor of relapse after drug
withdrawal
(4) Higher levels of γ globulin and IgG at
presentation
[38]
Perinuclear antinuclear
neutrophil cytoplasmic
antibodies (pANCA)
Peripheral nuclear
membrane component
Seen in type 1 AIH may help in diagnosis if
other tests are negative. [39]
active histologic inﬂammation have worse overall survival.
Histologic presence of bridging or multilobular necrosis is
associated with progression to cirrhosis in 82% cases and a
5-yearmortalityof45%inuntreatedpatients[74].Inasymp-
tomatic patients with inactive cirrhosis (deﬁned as no or
limited inﬂammation), corticosteroidtherapy has not shown
to improve survival. Patients without cirrhosis who undergo
treatment have a 10–20 year survival probability more than
80%, similar to the general population [71]. Retrospective
analysis of patients with mild disease has demonstrated
the possibility of long-term survival without treatment,
but very careful follow-up is required. Untreated patients
may, rarely, recover spontaneously, but improvement is less
common than treated patients, and long-term survival is
lower [75]. AIH can have unpredictable and varying disease
activity and ultimately the majority of patients with active
inﬂammation willwarrant therapy.Indicationsfortreatment
are listed in Table 3 a n da r eb a s e do nt h ep r e s e n c ea n d
severity of hepatic inﬂammation. The indications are also
reﬂective of risk factors for disease progression as severely
abnormal liver enzyme elevation, incapacitating symptoms,
histological presence of interface hepatitis, bridging necrosis,
or multiacinar collapse portend a worse prognosis without
treatment.6 Hepatitis Research and Treatment
Table 3: Indications for treatment of autoimmune hepatitis.
Absolute Relative None
Clinical Incapacitating
symptoms
Symptoms
(Fatigue,
arthralgia,
Jaundice,
AbdominalPain)
Asymptomatic
Laboratory
AST ≥ 10 fold
ULN
AST ≥ 5f o l d
ULN and
HG ≥ 2f o l d
ULN
AST or HG less
than absolute
criteria
Normal or near
normalAST and
γ Globulins
Histology
Bridging
necrosis or
Multiacinar
necrosis on
Histology
Interface hepatitis
Inactive
cirrhosis or mild
portal hepatitis
∗Relative Contraindications to immunosuppressant therapy-Osteopenia,
Emotional Lability, Hypertension, Diabetes, Mild Cytopenia
∗AbsoluteContraindicationstoAzathioprineor Prednisone-Vertebralcom-
pression, Psychosis, Uncontrolled hypertension, Brittle Diabetes, Severe
Cytopenia (WBC count < 2.5 × 109/L, Platelet count < 50 × 109/L),
Complete deﬁciency of Thiopurine methyl-transferase enzyme, Known
intolerance to prednisone or azathioprine
AST-Aspartate aminotransferase HG-Hypergammaglobulinemia ULN-
Upper limitof normal.
5.2.TreatmentRegimens. Prednisonealone(60mgdailywith
taper down to 20mg daily in 4 weeks) or at a lower dose
(30mg with taper down to 10mg daily in 4 weeks) in
combination with azathioprine (50mg daily) is the most
eﬀective treatment regimen studied in randomized clinical
trials [76]. The preferred regimen is listed in Table 4.B o t h
regimens are similarly eﬀective and diﬀer only in the fre-
quency of side eﬀects. Histologic improvement lags behind
clinical and laboratory resolution by 3 to 8 months, and
therapy should be continued for at least 3–6 months beyond
this point of improvement. Treatment is often maintained
for at least 2 years before withdrawal of drug therapy is
considered. The end points for treatment include remission,
treatment failure, incomplete response, or development of
drug toxicity. Their criteria and subsequent intervention are
summarized in Figure 2.
Prednisone is used alone in patients with severe cytope-
nias, active malignancy, pregnant or contemplating preg-
nancy, and those with complete thiomethylpurine trans-
ferase (TPMT) enzyme deﬁciency. Combination therapy is
associated with lesser side eﬀectsand is preferred when treat-
mentisexpected to bemore than6 monthsand inpatientsat
risk of side eﬀects including postmenopausal women, brittle
diabetics, labile hypertensive, and osteoporotic patients.
Therapy mayspanoverseveralyearsandhencetreatment
side eﬀects must be taken into consideration. Corticos-
teroids can cause weight gain, central obesity, moon facies,
prominent supraclavicularfat pad, acne, bruising, cutaneous
striae, cataracts, glaucoma, peptic ulcers, deterioration of
hypertension and diabetic control. Long-term side eﬀects
include increased risk of fractures secondary to osteoporosis
and avascular necrosis of bone. Patients with brittle dia-
betes, severe osteoporosis, vertebral compression fractures,
psychosis, obesity, and uncontrolled hypertension should be
carefully evaluated for a treatment beneﬁt before starting
corticosteroids. If severity of disease necessitates corticos-
teroid therapy, adequate measures should be instituted to
control the comorbid conditions [56]. In patients with
mild disease or relative contraindications to prednisone,
budesonide 3mg TID (in place of prednisone) is an option
to reduce overall treatment side eﬀects with no impairment
of eﬃcacy[77, 78]. Its beneﬁtsare derived from the 90% ﬁrst
pass metabolism which results in less steroid-induced side
eﬀects while maintaining eﬃcacy.
5.3. Alternative Treatments. Alternative regimens must be
considered in several circumstances: after treatment failure
with prednisone (60mg daily) or prednisone (30mg daily)
and azathioprine (150mg daily), incomplete response to
conventionaltherapy, orintolerancetoconventionaltherapy.
Mycophenolate mofetil (2g daily) has shown improvement
in 39–84% patientswho were unable to tolerate azathioprine
but use was limited by side eﬀects (nausea, vomiting, rash,
pancreatitis, diarrhea, cytopenia) [79–81]. Patients in these
studies were also treated with steroids in conjunction with
Mycophenolate mofetil. There are studies demonstrating
beneﬁt to the use of cyclosporine (in conjunction with
prednisone) for patients refractory to standard therapy. In
addition, a report suggests some beneﬁt to tacrolimus, but
hasnotbeenevaluatedin randomizedclinicaltrials[82].The
risk of toxicity must be weighed with these and other agents.
Ursodeoxycholic acid has been studied in randomized trials
and unfortunately was not found to be of beneﬁt [83].
5.4. Treatment of Relapse. Relapse is characterized by an
increase in the serum aminotransferase levels to at least
threefold normal. Relapse occurs in 50% to 86% of patients,
most often during the ﬁrst 6 months after the termination of
therapy(50%).Theﬁrstrelapseafterdrugwithdrawal should
be retreated with a combination of prednisone plus azathio-
prineatthesame treatment regimenaswiththeinitialcourse
of therapy and then tapered to monotherapy with either
azathioprine (2mg/kg daily) as a long-term maintenance
therapy or indeﬁnite low-dose prednisone (10mg daily) in
patientsintolerantofazathioprine.Gradualwithdrawal from
maintenance therapy maybe attemptedagain after atleast 24
months of treatment and continued normal serum AST or
ALT level only after careful beneﬁt risk evaluation in patients
whohadpreviouslyrelapsed.Repeatedrelapse(>2times)has
been associated with worse outcomes [84].
5.5. Liver Transplantation (LT). AIH is the underlying cause
for 4%–6% cases of liver transplants done in the Western
world [85, 86]. It usually results from a failure to diagnose
and treat AIH as an etiology of cirrhosis, inadequate
response or intolerance to immunosuppressive therapy, or
noncompliance with treatment. Treatment failure requiring
transplant is more often associated with the HLA genotype
DRB1∗0301[87].Livertransplantation shouldbeconsideredHepatitis Research and Treatment 7
Drug treatment
Corticosteroids (CS) and
Remission
-Absence of symptoms
-Normal bilirubin
-Normal histology or inactive
cirrhosis
Incomplete response
-Some or no improvement in
clinical, , laboratory and
histological features despite
compliance with therapy for
2–3years, without worsening
of condition
Failure of therapy
-Worsening clinical, , laboratory
and histological features
despite compliance with
therapy or development of
jaundice, , ascites or hepatic
encephalopathy
Drug Toxicity
-Development of symptomatic
osteopenia, emotional instability,
poorly controlled hypertension,
brittle diabetes, progressive
cytopenia, or pancreatitis
-
-
-
Gradual taper of prednisone
o v e r6w e e k s
taper and every 3–6months after
stopping therapy
2.5 mg/month until lowest level
possible (≤10 mg daily) to
prevent worsening of serum AST
or ALT abnormalities or
azathioprine (2mg/kg daily)
High dose prednisone
Azathioprine
Reduction in dose or
discontinuation of
oﬀending drug
Relapse
Restart CS and AZA
Inactive
Monitor lab tests
Indeﬁnitely
Liver transplant
Empiric
Cyclosporine/tacrolimus
Empiric
Mycophenolate
azathioprine (AZA)
-Normal serum transaminases
-Normal γ globulin level
Reduction in prednisone dose by
± high dose
Mofetil
γ globulin every 3weeks during
-AST, ALT, total bilirubin and
Figure 2: Endpoints for Immunosuppressive treatment with course of action in AIH.
Table 4: Treatment regimen for autoimmunehepatitis.
Combination therapy Monotherapy
Prednisone (mg/day) Azathioprine (mg/day) Prednisone (mg/day)
30mg × 1 week 50mg 60mg × 1 week
20mg × 1 week 50mg 40mg × 1 week
15mg × 2weeks 50mg 30mg× 2 weeks
10mg maintenance dose 50mg 20mg maintenance dose
in patients with AIH and acute liver failure, decompen-
sated cirrhosis with a MELD score ≥15, or hepatocellular
carcinoma meeting criteria for transplantation [56]. LT for
AIH is very successful with 10-year patient survivals of
approximately 75% [88]. A combination of prednisone and
a calcineurin inhibitor (tacrolimus more frequently than
cyclosporine) is the most common immunosuppression
regimen after LT. Despite this, AIH can recur in transplanted
liversoroccurde novoin livertransplants done fornon-AIH
conditions, but discussion of this is beyond the scope of this
review article.
6.Other Important Dimensions of AIH
6.1. Pregnancy and AIH. AIH can improve during preg-
nancy, and this may enable reduction in immunosuppressive8 Hepatitis Research and Treatment
therapy. The greatest risk is prematurity, but fetal mortality
has been reported to be as high as 21% [89]. Occurrence of
adverse outcome of any type is 26%. Perinatal mortality is
4%, and maternal mortality 3% [90]. Maternal antibodies
to SLA and extractable nuclear antigens (Ro/SSA) have
been associated with a more complicated pregnancy [89].
Preconceptional counseling is advised and immunosuppres-
sive therapy should be modiﬁed if possible. Azathioprine
is an FDA category D drug and safety in pregnancy has
not been well established in human studies. Although
increased number of birth defects have not been reported
in neonates of women receiving this treatment and no
adverse consequences of breast feeding have been noted by
treated mothers [91, 92], congenital malformations have
beenreported inpregnant mice, and, thusthere isa potential
risk for teratogenicity. This justiﬁes exercising caution when
using in pregnancy, thus the mainstay of treatment in
pregnancy is prednisone at as low dose as possible. AIH
commonly exacerbates following delivery, therefore therapy
must be resumed (if stopped) or increased 2 weeks prior
to anticipated delivery and continued in the postpartum
period.
Women with advanced cirrhosis and portal hypertension
are at high risk for variceal hemorrhage during pregnancy
[91]. Pregnancy should be avoided and eﬀective contracep-
tion should be advised in these patients.
6.2. AIH, Cirrhosis, and Hepatocellular Carcinoma (HCC).
AIH is associated with chronic inﬂammation that may
proceed to cirrhosis and end-stage liver disease which also
puts AIH patients at risk of developing HCC. However,
unlike other cohorts of cirrhotic patients, the majority of
patients with AIH respond well to immunosuppression and
in those whom enter a sustained remission, the potential
exists to retain a near normal life expectancy. However, the
interactions of disease activity, response to treatment, and
other factors in relation to the risk of HCC development
in AIH are unknown. Although the development of HCC
in patients with AIH and cirrhosis is considered a rare
occurrence, the true incidence remains unknown due to
the paucity of published data addressing this issue. A large
prospectively obtained cohort at a single center (n = 243)
determined a rate of HCC development of 1.1% per year,
with equal proportions among men and women [92]. The
median duration from time of conﬁrmed cirrhosis to a
diagnosisofHCCwas 102.5months (range12–195months).
Not surprisingly, HCC was found to occur more frequently
in patients with cirrhosis at presentation (9.3% versus 3.4%,
P = .048) or history of variceal bleed as the index presenta-
tion of AIH (20% versus 5.3%, P = .003). Median survival
in patients whose HCC was diagnosed on surveillance was
higher (19 months versus 2 months) compared with patients
presenting symptomatically (P = .042)[92]. The majority of
patientsdevelopHCCafter having cirrhosis for anaverageof
9 years, and although the incidence of HCC is less common
than in other chronic liver diseases, the risk may be suﬃcient
to undertake surveillance in all patients with cirrhosis with
AIH who are candidates to undergo curative therapies.
7.ConclusionandFuturePerspectives
Autoimmune hepatitis is one of the few liver diseases with
excellent response to therapy. On the other hand, it still
remains a liver disease with many unanswered questions,
particularly in respect to its etiology and pathogenesis. There
is signiﬁcant heterogeneity in its presentation that may mask
its identity, aﬀect its clinical behavior, and confound its
management. It may start with a fulminant course, and
the diagnosis should not be overlooked when dealing with
patients with acute liver failure. Alternatively, it may behave
as a slowly progressing disease, and it is still controversial
whether those patients need immunosuppressive treatment
at all. There is no prescribed minimum or maximum
duration of treatment. Over the last decade, remarkable
progress has been made in understanding and clarifying
the areas of diagnosis with introduction of classiﬁcation
criteria, and broadening therapeutic options, with trial of
several new medications likebudesonideand mycophenolate
mofetil, and more in the pipeline. Management, however,
still faces several other important issues, such as in children,
the elderly, in males, and during the preconception period,
pregnancy, and lactation. A key to successful management is
thinkingofit,recognizingthenonclassicalpresentations,and
individualizing therapy.
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